Health Rights of Indian Children

Respecting the Health Rights of India’s Children

Syllabus:

GS Paper – 2: Issues Related to ChildrenGovernment Policies & Interventions

GS Paper – 3:  Social MediaEffects of Globalization on Indian Society

Why in the News ?

The recent death of 25 children in Madhya Pradesh due to contaminated cough syrup has once again exposed serious lapses in India’s drug regulation system, especially for paediatric medicines. Despite a ban on certain formulations for children under four years, regulatory oversight and safety monitoring remain alarmingly weak.

The Tragedy and Regulatory Accountability:

• Shock and neglect: The deaths of 25 children due to toxic cough syrup have raised grave concerns about drug quality control and public health governance in India.
• Banned formulations: The Union Health Ministry had already banned certain cough syrups for children below 4 years in April 2025 due to contamination risks.
• Regulatory confusion: The Central Drugs Standard Control Organisation (CDSCO) manages large drug manufacturers and export approvals, while State Drug Control Officers oversee smaller units—creating fragmented accountability.
• Ethical lapse: Reports suggest that the paediatrician involved received a commission of ₹2.54 per bottle, symbolizing the moral decay in the system.
• Public outcry: The tragedy underscores the urgent need to strengthen pharmacovigilance and reform India’s regulatory architecture for children’s medicines.

Constitutional and Legal Mandate for Child Protection:

• Directive principle: Article 39(f) of the Indian Constitution directs the State to ensure that children are given opportunities to develop in a healthy manner.
• Existing frameworks: India has around 13 major policies for children—from the National Policy for Children (1974) to the India Newborn Action Plan (2014).
• Legal protections: Nearly 10 legislations, such as the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act and Aadhaar Act, have child-centric provisions.
• Narrow focus: However, most of these laws focus on child labour and sexual exploitation, neglecting the medical safety dimension.
• Right to health: Ensuring safe paediatric medication is part of the fundamental right to health and dignity under Article 21.

Pharmacovigilance Gap and Therapeutic Orphanhood

• Unique physiology: As Harry Shirkey observed, children are “therapeutic orphans”—their pharmacodynamics differ significantly from adults.
• Trial limitations: Due to ethical constraints, clinical trials rarely include children, resulting in lack of dosage guidelines.
• Etrapolated dosages: In India, adult dosage standards are often improperly scaled down for children, leading to toxicity or underdosing.
• Research deficit: The absence of paediatric-specific research and standardized formulation guidelines increases risks of unsafe administration.
• Systemic neglect: Paediatric pharmacovigilance remains poorly institutionalized, leaving children vulnerable to drug-related morbidity and mortality.

International Best Practices and India’s Lag:

• Global models: The European Union follows the Paediatric Use Marketing Authorisation (PUMA), while the United States enforces the Best Pharmaceuticals for Children Act (BPCA).
• Research incentives: These frameworks provide financial incentives for paediatric drug research and safer formulation development.
• India’s policy gap: India lacks specific legislation or policy for paediatric medicine safety and relies on general drug control guidelines.
• Dependency and poverty: Children depend on parents or guardians for healthcare; high drug costs can push families deeper into poverty cycles.
• Policy necessity: India urgently requires a dedicated Paediatric Drug Safety Policy, ensuring affordable, evidence-based, and regulated access to medicines for children.

Essential Medicine Concept and Public Health Practice:

• WHO’s framework: The World Health Organization (WHO) defines Essential Medicines (EML) as those meeting priority health needs—safe, effective, and affordable.
• Children’s list: WHO also introduced the Essential Medicines List for Children (EMLc) to guide national updates.
• India’s gaps: While India revises the adult EML periodically, the EMLc remains outdated, reflecting a policy blind spot.
• Safe dispensing: Regular training of pharmacists and caregivers, correct dosage awareness, and side-effect monitoring are critical.
• OTC regulation: Strong regulation of over-the-counter (OTC) drugs for cough, cold, and fever is essential to curb misuse—especially in urban areas where self-medication is rampant.

Challenges in Ensuring Paediatric Drug Safety :

• Regulatory fragmentation: The split authority between Central and State drug regulators leads to weak enforcement and inconsistent standards.
• Lack of paediatric data: India’s pharmacological data for children largely depends on foreign research, overlooking genetic and environmental differences.
• Inadequate infrastructure: There is a shortage of child-specific testing labs, safety monitoring units, and trained pharmacovigilance personnel.
• Economic incentives: Pharmaceutical companies prioritise adult formulations for profitability, ignoring the low-demand paediatric segment.
• Weak consumer awareness: Parents often lack drug literacy, leading to self-medication, misuse, and poor adherence to dosage guidelines.
• Over-reliance on exports: India’s ambition as the pharmacy of the Global South increases pressure but also reputational risks, as seen in cough syrup-related deaths in Gambia, Uzbekistan, and Indonesia.
• Unregulated OTC market: Easily available unprescribed drugs, particularly for children, often escape quality checks, heightening public health hazards.
• Limited coordination: Absence of a national paediatric pharmacovigilance database prevents early detection of adverse effects or contaminated batches.
• Ethical challenges: Conducting clinical trials on children raises ethical dilemmas, limiting evidence generation.
• Policy inertia: Despite repeated WHO warnings, India’s paediatric drug regulation continues to be reactive rather than preventive.

Way Forward for a Child-Safe Pharmaceutical Policy :

• Dedicated legislation: Enact a Paediatric Pharmaceuticals Safety Act, drawing from global models like PUMA and BPCA.
• Unified regulation: Create a National Child Drug Regulatory Authority integrating CDSCO and State regulators for single-window oversight.
• Data generation: Establish national-level research hubs to collect India-specific paediatric pharmacology data.
• Regular EMLC revision: Institutionalize a biannual review of the Essential Medicines List for Children to keep pace with new formulations.
• Stringent OTC control: Mandate prescription-only access for paediatric drugs with digital tracking of sales to prevent misuse.
• Capacity building: Train pediatricians, pharmacists, and frontline health workers on paediatric drug safety and adverse event reporting.
• Awareness campaigns: Launch nationwide programmes educating parents and caregivers on safe drug administration and label reading.
• Incentivise research: Provide tax incentives and grants for pharma firms investing in paediatric formulations and trials.
• Global accountability: Ensure that exported medicines meet WHO-GMP standards with third-party verification.
• Legal enforcement: Introduce strict penalties for manufacturers and medical professionals found guilty of negligence or malpractice in paediatric drug dispensing.

Conclusion :

India’s children are not “small adults.” Their health demands specialized attention, tailored medication, and ethical governance. The cough syrup tragedy is a wake-up call for the State to align law, science, and compassion. Protecting children’s health is not charity—it is the constitutional and moral duty of a civilized nation.

Mains Practice Question :

“India’s pharmacovigilance and regulatory systems remain inadequately prepared to protect children’s health and drug safety.” Discuss in the context of recent incidents involving contaminated paediatric syrups. Suggest institutional and policy measures to strengthen child-specific medicine regulation under the Right to Health framework.